|Bid||7.31 x 1000|
|Ask||7.35 x 3100|
|Day's Range||7.05 - 7.48|
|52 Week Range||2.85 - 7.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) has approved oral TPOXX® (tecovirimat) for the treatment of smallpox to mitigate the impact of a potential outbreak. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication.
SIGA Technologies Inc. (SIGA) rose 9.6% in Friday afternoon trade on the Food and Drug Administration's approval of its TPOXX, the first-ever smallpox therapy. The contagious and often-deadly disease -- described as "one of the world's most devastating diseases known to humanity" by the World Health Organization -- has been considered eradicated since 1980 due to global immunization, but there have been fears that it could be used for bioterrorism, the FDA said. To establish the product's safety, it was tested in 359 healthy humans who did not have smallpox, while the efficacy findings that the approval was based on were in animals.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, which comprises countermeasures for biological, chemical, radiological and nuclear attacks as well as vaccines and therapies for emerging infectious diseases and health preparedness to address serious unmet medical needs, today announced the publication of data in the New England Journal of Medicine from its pivotal human safety and animal efficacy studies of its oral formulation of TPOXX® (tecovirimat). These results support the antiviral activity and favorable safety profile of TPOXX for the treatment of smallpox. “Smallpox is both highly contagious and highly lethal and there is growing concern that smallpox could be used as a potential bioweapon,” said Phil Gomez, PhD, SIGA’s Chief Executive Officer.
SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 12:30 pm ET on Friday, June 8, 2018 in New York. Dr. Gomez will provide a corporate update and discuss the company’s lead investigational product TPOXX®, an antiviral drug targeting the treatment of smallpox. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...
SIGA Technologies, Inc. (SIGA) (SIGA), a health security company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee meeting on oral TPOXX®, a small molecule antiviral treatment for smallpox. The panel, comprised of independent medical experts, voted unanimously, 17 to 0, that the benefits of TPOXX outweigh its risks. “We are pleased that the advisory panel believes strongly in the benefits of TPOXX.
The panel, comprised of independent medical experts, will consider whether the benefits of TPOXX outweigh its risks. The FDA has previously announced that its target final action date for the oral TPOXX NDA is August 8, 2018.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment ...
Categories: Yahoo FinanceGet free summary analysis SIGA Technologies, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of SIGA Technologies, Inc. – Achillion Pharmaceuticals, Inc., Emergent BioSolutions Inc., SciClone Pharmaceuticals, Inc., Novavax, Inc., Sarepta Therapeutics, Inc., Chimerix, Inc., BioCryst Pharmaceuticals, Inc. and Newlink Genetics Corporation (ACHN-US, ... Read more (Read more...)